Markets
Palisade Bio, Inc. (PALI)
PALINASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$1.12
-0.0700 (-5.88%) today
Regular session, Nov 10, 3:28 PM ET
-5.88% 1D
- Market cap
- $195.18m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $1.12 to $1.20
- 52-week range
- $1.08 to $2.86
- Average volume
- 3.46m
- Previous close
- $1.19
Analysts
5 coveringBuy5 buy, 0 hold, 0 sell
Targets a year out average $10.17, +808.0% from here
$6.00now $1.12$25.00
Earnings
next estimate $-0.0600Next report
Mar 2026
-25.0%
Jun 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | $500.0k |
| Gross profit | – | – | – | $500.0k |
| Operating income | -$2.92m | -$9.98m | -$10.75m | -$11.70m |
| Net income | -$2.87m | -$8.90m | -$9.60m | -$10.57m |
News
8 latest- Palisade Doses First Patient In Phase 2b Ulcerative Colitis Trial; Data Expected Q4 2027 RTTNews · Oct 29, 2026
- Palisade Bio Rises 9% As PALI-2108 Shows Early Activity In Crohn's Disease RTTNews · Oct 20, 2026
- Palisade Bio Presents PALI-2108 Data Supporting Phase 2 Trials In Inflammatory Bowel Disease RTTNews · Oct 12, 2026
- Raymond James Initiates Coverage of Palisade Bio with OutperformFintel · Oct 9, 2026
- Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’sMarketBeat · Sep 27, 2026
- Palisade Wins Health Canada Clearance For Phase 2 ASCENTRA-UC Study RTTNews · Sep 23, 2026
- Palisade Bio Gets FDA Clearance For PALI-2108 IND In Crohn's Disease RTTNews · Sep 23, 2026
- Palisade Bio Q2 Net Loss Expands; Plans Phase 2 ASCENTRA-UC Trial Enrollment In H2 2026; Stock Down RTTNews · Aug 11, 2026
The company
Palisade Bio is a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated and fibrotic diseases. Its lead program, PALI-2108, is in Phase 2 development in ulcerative colitis, with a Phase 2 study in Crohn's disease underway.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- palisadebio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.